Relation between cost of drug treatment and body mass index in people with type 2
diabetes in Latin America by Elgart, Jorge Federico et al.
RESEARCH ARTICLE
Relation between cost of drug treatment and
body mass index in people with type 2
diabetes in Latin America
Jorge Federico Elgart1*, Mariana Prestes1, Lorena Gonzalez1,2, Enzo Rucci1,3, Juan
Jose Gagliardino1, for the QUALIDIAB Net study group¶
1 CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata), School of
Medicine, National University of La Plata, La Plata, Argentina, 2 School of Health Economics and
Management of Healthcare Organizations, Faculty of Economic Sciences, National University of La Plata, La
Plata, Argentina, 3 III-LIDI, Faculty of Informatics, National University of La Plata, La Plata, Argentina
¶ Membership of the QUALIDIAB Net Study group can be found in the Acknowledgments section.
* jelgart@cenexa.org
Abstract
Aims
Despite the frequent association of obesity with type 2 diabetes (T2D), the effect of the for-
mer on the cost of drug treatment of the latest has not been specifically addressed. We stud-
ied the association of overweight/obesity on the cost of drug treatment of hyperglycemia,
hypertension and dyslipidemia in a population with T2D.
Methods
This observational study utilized data from the QUALIDIAB database on 3,099 T2D patients
seen in Diabetes Centers in Argentina, Chile, Colombia, Peru, and Venezuela. Data were
grouped according to body mass index (BMI) as Normal (18.5BMI<25), Overweight
(25BMI<30), and Obese (BMI30). Thereafter, we assessed clinical and metabolic data
and cost of drug treatment in each category. Statistical analyses included group compari-
sons for continuous variables (parametric or non-parametric tests), Chi-square tests for dif-
ferences between proportions, and multivariable regression analysis to assess the
association between BMI and monthly cost of drug treatment.
Results
Although all groups showed comparable degree of glycometabolic control (FBG, HbA1c),
we found significant differences in other metabolic control indicators. Total cost of drug treat-
ment of hyperglycemia and associated cardiovascular risk factors (CVRF) increased signifi-
cantly (p<0.001) with increment of BMI. Hyperglycemia treatment cost showed a significant
increase concordant with BMI whereas hypertension and dyslipidemia did not. Despite dif-
ferent values and percentages of increase, this growing cost profile was reproduced in
every participating country. BMI significantly and independently affected hyperglycemia
treatment cost.
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Conclusions
Our study shows for the first time that BMI significantly increases total expenditure on drugs
for T2D and its associated CVRF treatment in Latin America.
Introduction
Obesity represents a large and growing global health problem [1] significantly associated with
increased morbidity and mortality [2–5], decreased quality of life [6], and increased healthcare
costs [7].
Body fat distribution, particularly excess of visceral adipose tissue (VAT), usually called
abdominal obesity (AO), has been associated with greater health risk [8] such as development
of type 2 diabetes (T2D), cardiovascular disease (CVD), and serious hospitalization events [9–
11].
The Prospective Obesity Cohort of Economic Evaluation and Determinants (PROCEED)
study, a multinational observational-prospective internet-based cohort study comparing
healthcare utilization of overweight/obese people with and without AO, concluded that more
obese people had an increasing gradient of medical conditions, metabolic risk factors, and
healthcare utilization [12]. Similar changes were reported by Dilla et al following for a
12-month period 738 patients with a mean age of 66 years and BMI of 30.6 kg/m2: each unit
gain in BMI was associated with a 20.0% increase in costs for BMI gainers while loss of one
unit decreased these costs by 8.0% in non-BMI gainers [13]. Milder et al. also reported that
obese persons used more prescription drugs of several types, particularly cardiovascular drugs
(OR 3.83 in men and 2.80 in women) and diabetes drugs (OR 5.72 in men and 3.92 in women)
than normal weight persons [14]. Future healthcare costs were also higher for overweight per-
sons, especially for those with BMIs 30 kg/m2 [15].
Higher costs of medical treatment associated with obesity have also been observed at pri-
mary care level: the Counterweight Project Team reported that total prescribing volume was
significantly higher for the group with obesity and increased two- to four fold in the case of
drugs such as lipid regulators, β-adrenoreceptor drugs, drugs affecting the renin angiotensin
system, calcium channel blockers, sulphonylureas, biguanides and other drugs as well. This
increase was due to both the greater number of patients treated and the use of higher drug
doses [16,17].
Despite this large and concordant information, Cawley et al suggest that although informa-
tion on the effect of weight and weight loss on medical expenditures is critical for decision
makers to analyze cost-effectiveness of strategies for prevention and treatment of obesity, med-
ical care costs at specific levels of BMI are not well described [18]. Four major problems chal-
lenge this assessment: 1) different conditions affect people with and without obesity, and
therefore the correlation of medical expenditure with BMI depends not only on the effect of
BMI itself but also on the association of other unobserved characteristics; 2) errors in weight
and height data due to frequency of self-reporting rather than direct measurements [19,20]; 3)
casual association of independent and dependent variables; 4) medical expenditures are a non-
linear function of BMI, and therefore, accurately estimating medical expenditures at various
levels of BMI requires a nonlinear model. They concluded that savings from a given percent of
reduction in BMI depends on its initial value: the saving is greater the heavier the obese indi-
vidual is, and is even greater for those with diabetes. Thus, despite the frequent simultaneous
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presence of T2D and obesity, the specific effect of the latest on the cost of drug treatment of
this disease has not been addressed.
To provide an answer to this last issue, we now evaluated the association of overweight/obe-
sity and BMI on the cost of drugs used for treatment of hyperglycemia and associated cardio-
vascular risk factors (hypertension, dyslipidemia) in people with T2D.
Research design and methods
Study population and sampling
This Latin American observational study utilized data from the QUALIDIAB database which
includes patients seen at public and private Diabetes Service Centers in Argentina, Chile,
Colombia, Peru, and Venezuela. QUALIDIAB is a program that evaluates the quality of care
provided to people with diabetes in Latin America. Development of the QUALIDIAB net was
based on the benefits of a common data registry in different countries to enable comparison of
data to correct mistakes and strengthen successful strategies. The QUALIDIAB database
includes clinical, metabolic and therapeutic indicators, information on micro and macrovas-
cular complications, the rate of use of diagnostic and therapeutic elements and annual patient
hospitalization [20–22]. All this information is reported directly by physicians during personal
interviews; thereafter, data are loaded and stored in anonymous format for subsequent
analysis.
We included all patients having filled out a QUALIDIAB form between January 2011 and
June 2014. Therefore, records of 4124 patients with T2DM were analyzed. Their country of
origin was Argentina (2246), Chile (200) Colombia (654), Peru (651), and Venezuela (373).
1025 records were excluded because we were unable to calculate BMI (due to missing data on
weight, height or both); consequently, the final number of people used for the statistical analy-
sis was 3,099.
Data analysis
BMI was calculated for each participant: weight in kilograms/ (height in meters)2. Final BMI
data were classified and divided according to the WHO definition into three groups: Normal
weight (18.5 BMI< 25), Overweight (25 BMI < 30) and Obese (BMI 30) [1]. Within
each category, we utilized clinical and metabolic indicators, as well as type of drug treatment
(drug and daily dose prescribed). Drug treatment was classified by drug prescription into
three groups (Hyperglycemia, Hypertension and Dyslipidemia).
Cost of drug treatment calculation
Monthly expenditure on drugs was estimated by micro-costing. For that purpose, we calcu-
lated a mean unit retail price per milligram of each drug or per insulin units in each country
(except Venezuela). Drug costs were obtained from representative databases in Argentina
(Alfabeta.net), Colombia (SISMED), Chile (Kairos@) and Peru (Observatorio de Precios—
DIGEMID); and then converted to US dollars ($) according to the exchange rate in August
2014 in each participating country. With these data, we estimated an average price for each
drug. Monthly drug treatment expenditures was calculated individually for each patient
according to resource utilization, as follows: the daily dose was multiplied by 30 (a month),
then multiplied by the average price, resulting in monthly expenditures. Since the average
price of each drug used was the same for different settings and countries, drug treatment cost
reflects only the extent of drug utilization.
Drug treatment cost and BMI in type 2 diabetes
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Statistical analysis
Statistical analyses utilized the Statistical Package for Social Sciences version 15 (SPSS Inc, Chi-
cago, IL, US). Descriptive statistics are presented as percentages and mean ± standard devia-
tion (SD). Group comparisons for continuous variables utilized parametric or nonparametric
tests according to the data distribution profile. The Chi-square test was used to estimate differ-
ences between proportions. Multivariable regression analysis was used to evaluate the associa-
tion between cost of drug treatment and BMI. For regression analysis, to account for the
skewed distribution of cost of drug treatment we developed a generalized linear model (GLM)
with log-link function to estimate the association between drug treatment cost and BMI,
patient demographic characteristics, diabetes treatments, complications and comorbidities.
When several independent variables were highly correlated with each other (correlation coeffi-
cient0.25), only 1 variable was included in the model. For example, age and diabetes dura-
tion are highly correlated, so age was deleted from the models. While we did not consider
interaction effects for our analyses, the level of significance was established as p0.05.
Ethical statement
The study protocol was analyzed and approved by the Bioethical Committee of the National
University of La Plata. This study was developed according to Good Practice Recommenda-
tions (International Harmonisation Conference) and the ethical guidelines of the Helsinki
Declaration. Informed consent was waived because this retrospective study involves secondary
analysis of existing database which was de-identified and anonymously stored to protect pri-
vate information. Therefore, this procedure ensured compliance with the National Law 25.326
of Personal Data Protection.
Results
Clinical and metabolic characteristics of the study population classified according to its BMI
showed that only 16% of participants had BMI within the normal range, 38% were overweight,
and the remaining 46% were obese (Table 1). The percentage of men was significantly greater
in the overweight group than in the other two groups. Mean age was comparable in the normal
and overweight groups but was significantly lower (younger) in the obese group. Duration of
diabetes was lower in obese than overweight group, while was comparable in the normal and
overweight groups. Although systolic and diastolic blood pressure values were within normal
range in all groups, they were significantly lower in the normal weight compared to the obese
group.
Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) showed comparable values in
all groups; however, they were all above those recommended by the American Diabetes Asso-
ciation and European Association for the Study of Diabetes (ADA/EASD) guideline [23].i.e.
all studied population had a comparable degree of abnormal glycometabolic control.
Triglyceride values were above those recommended by international guidelines in the over-
weight and obese group, being significantly higher in the latter.
Significant differences between groups were found in hyperglycemia treatment (Table 2).
The proportion of patients treated with only diet and physical activity as well as those on oral
monotherapy decreased significantly in overweight/obese people, whereas administration of
combined oral therapy alone or associated with insulin was significantly higher in the over-
weight and obese groups. No significant differences among groups were recorded in people
treated only with insulin.
Total monthly per capita costs of drug treatment of hyperglycemia and associated cardio-
vascular risk factors increased significantly with BMI category (p<0.001, Table 3). While drug
Drug treatment cost and BMI in type 2 diabetes
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treatment of hyperglycemia alone showed a similar increase trend and percentage, no signifi-
cant differences were observed in hypertension and dyslipidemia drug therapy.
Even with a comparable degree of glycometabolic control, overweight and obese people
increased their monthly per capita cost of hyperglycemia medications by 14 and 38%, respec-
tively (Table 3). Each year, overweight and obese people spent, respectively, US$172.80 and US
$448.80 more than normal weight patients.
Since the study includes different numbers of participants from each country, we tested
whether BMI and total drug treatment cost showed similar relationship or merely reflected
results in a particular country with a larger representation. Although the values differed and
the percentage of increase varied, the growing cost profile was reproduced in every participat-
ing country (Fig 1). In this regard, the largest and lowest increases were recorded in Venezuela
and Colombia, respectively. Since the average price of each drug utilized was the same in the
different countries, these differences might be probably ascribed, at least partly, to the quantity
of drug utilization.
Multivariable regression analysis showed that total expenditure of drugs was significant and
independently associated with gender, BMI, systolic blood pressure (SBP) and LDL-choles-
terol, levels, hypertension, dyslipidemia and treatment of T2D (Table 4). Total expenditure on
drugs was 7.3% higher in male than in female while total drugs treatment costs were higher in
patients with hypertension or dyslipidemia (1.417 and 2.077, respectively). Further, each point
of change in BMI was associated with a 1.3% increase in the total drugs expenditure. The anal-
ysis also showed that expenditure for hyperglycemia drugs treatment was significantly
Table 1. Characteristics of the study population.
Parameter All Normal weight
(18.5 BMI < 25)
Overweight (25 BMI < 30) Obesity (BMI 30)
Value n Value n Value n Value n
Men (%) 42.3 3099 40.0 495 47.1 * 1185 39.1 † 1419
Age (years) 62.1 ± 11.8 3079 63.9 ± 12.4 489 63.3 ± 11.7 1179 60.4 ± 11.4*† 1411
Diabetes Duration (years) 10.8 ± 9.0 2391 11.0 ± 9.7 387 11.5 ± 9.4 896 10.1 ± 8.4 † 1108
BMI (kg/m2) 30.1 ± 5.8 3099 23.0 ± 1.4 495 27.4 ± 1.4* 1185 34.9 ± 4.9*† 1419
SBP (mmHg) 129.9 ± 17.5 3053 124.8 ± 18.1 486 129.8 ± 17.5 * 1170 131.7 ± 16.9*† 1397
DBP (mmHg) 77.3 ± 10.9 3049 73.1 ± 10.9 486 76.5 ± 10.3 * 1168 79.3 ± 10.9 *† 1395
FBG (mg/dL) 152.3 ± 84.0 2842 158.2 ± 115.3 441 148.7 ± 76.6 1073 153.3 ± 77.1 1327
HbA1c (%) 7.7 ± 1.9 2739 7.7 ± 2.3 440 7.7 ± 1.8 1032 7.7 ± 1.8 1267
[mmol/mol] [61 ± 20.8] [61 ± 25.1] [61 ± 19.7] [61 ± 19.7]
HbA1c7% (%) 43.9 2739 48.2 440 43.1 1032 43.0 1267
Total Cholesterol (mg/dL) 185.6 ± 45.9 2749 181.2 ± 45.2 422 185.6 ± 44.7 1050 187.2 ± 46.9 1277
HDL-c (mg/dL) 47.4 ± 21.1 2509 51.3 ± 29.1 393 46.9 ± 14.7 * 946 46.6 ± 22.2 * 1170
LDL-c (mg/dL) 106.7 ± 35.9 2413 104.6 ± 38.4 373 107.3 ± 35.6 918 106.9 ± 35.5 1122
Triglyceride (mg/dL) 171.6 ± 108.4 2671 143.5 ± 87.8 412 162.0 ± 100.2 * 1002 188.4 ± 117.7 *† 1257
Complications (%) 56.1% 2539 59.5% 395 56.3% 969 54.8% 1175
Hypertention (%) 65.3% 2024 53.7% 266 63.3% * 750 71.0% *† 1008
Dyslipemia (%) 62.6% 1939 60.4% 299 59.4% 704 66.0% † 936
Each value represents mean ± SD (standard deviation); BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting
blood glucose.
*Significant compared with normal weight (P < 0.05)
† Significant compared to overweight (p < 0.05).
https://doi.org/10.1371/journal.pone.0189755.t001
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associated with gender, duration of diabetes, BMI and LDL-cholesterol values, dyslipidemia,
T2D complications and type of drugs employed.
Discussion
Our data show that increase in BMI is associated with a parallel growth in overall drugs treat-
ment cost of hyperglycemia and its associated cardiovascular risk factors. This effect was
observed despite comparable values for FBG/HbA1c and blood pressure found in each BMI
classified group. However, impaired serum lipid profile, characterized by significantly high tri-
glyceride level, was recorded mainly in the overweight/obese groups. Based on these results
and the fact that treatment costs were expressed per capita, we could assume that people with
higher BMI required larger quantities of drugs to attain a given blood glucose treatment target.
Table 2. Type of hyperglycemia medications treatment by BMI categories.
Treatment All Normal weight
(18.5 BMI < 25)
Overweight
(25 BMI < 30)
Obesity
(BMI 30)
% n % n % n % n
Only diet and Phys. activity 2.9 91 5.2 26 3.2* 38 1.9 *† 27
OAD Monotherapy 29.9 928 35.4 175 29.0* 344 28.8* 409
Metformin 84.5 770 75.0 132 82.8* 284 90.3*† 354
SU 10.3 94 14.8 26 12.2 42 6.6*† 26
DPP-4 4.5 41 10.2 18 4.1* 14 2.3* 9
Other (%) 0.7 6 0.0 0 0.9 3 0.8 3
Combined OAD (2 or more) 29.0 898 24.8 123 29.5 350 30.0 425
Metformin (%) 97.6 898 96.0 119 97.7 344 98.0 435
SU (%) 74.9 689 73.4 91 75.9 267 74.5 331
DPP-4 (%) 32.0% 294 35.5 44 32.4 114 30.6 136
Other (%) 8.2 75 1.6 2 4.5 16 12.8*† 57
Insulin + OAD (1 or more) 23.1 715 17.6 87 22.3 * 264 25.6 *† 364
Insulin alone 15.1 467 17.0 84 16.0 189 13.7 194
OAD: Oral antidibetics drugs; SU: sulfonylureas; DPP-4: dipeptidil peptidasa-4.
*Significant compared with normal weight (P < 0.05)
† Significant compared to overweight (p < 0.05).
https://doi.org/10.1371/journal.pone.0189755.t002
Table 3. Monthly cost of drug treatment per capita by risk factor and BMI categories.
Treatment
Normal weight
(18.5 BMI < 25)
Overweight
(25 BMI < 30)
Obesity
(BMI 30)
p value (between groups) b
Mean ± SD n Mean ± SD Ratioa n Mean ± SD Ratioa n
Hyperglycemia $61.0 ± 55.4 469 $69.6 ± 57.7 * 1.14 1147 $84.5 ± 76.3 *† 1.38 1392 <0.001
Hypertension $40.1 ± 30.1 232 $42.7 ± 33.3 1.06 666 $44.4 ± 37.6 1.11 908 0.289
Dyslipidemia $73.1 ± 36.8 234 $74.2 ± 41.8 1.02 534 $70.0 ± 39.5 0.96 702 0.088
Total cost (All together) $113.8 ± 83.8 495 $128.2 ± 89.3 * 1,13 1185 $151.2 ± 109.4 *† 1.33 1419 <0.001
Costs of treatment are expressed in US dollars ($).
aBased on Normal weight.
b Kruskall-Wallis test.
*Significant compared with Normal weight (p< 0.05; Mann-Whitney U test)
† Significant compared to Overweight (p< 0.05; Mann-Whitney U test).
https://doi.org/10.1371/journal.pone.0189755.t003
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This larger drug demand could be due to the negative impact of overweight/obesity on tissue-
insulin sensitivity [24].
Other authors have reported an incremental impact of overweight/obesity on health care
costs for people with diabetes. Yu et al found that in patients with diabetes who gained a mini-
mum of one pound between two weight measurements, the average 1-year total diabetes-
related health care cost following the second weight measure was significantly higher than the
corresponding measure for those who did not gain weight ($2,141 vs. $1,869, respectively;
p = 0.006). When weight gain and no gain were modeled separately, 1% weight loss was associ-
ated with a 5.8% ($131; p<0.01) decrease in diabetes-related cost; the economic benefit of
weight loss was higher in the group with BMI 30 kg/m2 [25]. Similarly, Apovian et al
reported that obesity is associated with a more than 13-fold increase in expenditure on antidia-
betic medications [26].
Despite differences in the magnitude of the cost increase, similar trends were reported
regarding the association of BMI on general drug consumption at every level of care complex-
ity [16,17,27,28] and in different health care settings [29–31]. Further, both old and new
reports [3,15] as well as current studies of care costs have shown the same trend [7,15].
Although with different values, we found similar association between BMI and medication
costs in each participating country (Fig 1). Since we cannot assure that overweight/obesity
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Fig 1. Total cost of drug treatment by country. NW: Normal weight (18.5 BMI < 25); OW: Overweight (25 BMI < 30); O: Obesity (BMI 30).
https://doi.org/10.1371/journal.pone.0189755.g001
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frequency was exactly the same in all of them, this potential difference could be one of the
causes for the different cost increase among countries. However, the persistence of a signifi-
cant difference in every country -large despite different values- plays in favor of the strength of
this phenomenon.
Higher BMI is also associated with higher indirect costs and lower productivity, conse-
quently, its negative impact affects not only health care costs but also many other social factors
[27,32,33].
Despite the known negative effects of overweight/obesity associated with T2D on health
care costs, productivity, and society, plus the availability of effective strategies for its preven-
tion and treatment [34,35], both obesity and T2D show progressive growth worldwide, reach-
ing epidemic levels [36].
Behavioral treatment of obesity at the primary care level including monthly counseling vis-
its and a choice of meal replacements or weight loss medication could be a cost-effective strat-
egy for obesity over the long term ( 10 years) [37]. More aggressive strategies such as
bariatric surgery, when appropriately prescribed, may lead to significant cost savings for health
care systems [38]. In fact, people with T2D who undergo bariatric surgery may also decrease
drug treatment costs compared to those in conventional treatment ($14,346 vs. $19,511;
Table 4. Multivariable regression analysis.
Explanatory
Variable
Model 1 Model 2
Total cost of drug treatment Cost of hyperglycemia drug treatment only
Original regression
coefficient
p
value
Exponential a 95% CI Original regression
coefficient
p
value
Exponential a 95% CI
Lower Upper Lower Upper
Intercept 3.310 0.000 27.397 19.959 37.607 3.333 0.000 28.012 18.916 41.481
Gender (male) 0.070 0.030 1.073 1.007 1.143 0.095 0.017 1.100 1.017 1.189
Diabetes Duration
(years)
0.003 0.161 1.003 0.999 1.007 0.013 0.000 1.013 1.008 1.018
HbA1c (%) 0.016 0.099 1.017 0.997 1.036 0.020 0.101 1.020 0.996 1.044
BMI (kg/m2) 0.012 0.000 1.012 1.006 1.018 0.022 0.000 1.022 1.015 1.029
SBP (mmHg) 0.002 0.019 1.002 1.000 1.004 -0.001 0.379 0.999 0.997 1.001
LDL- Cholesterol
(mg/dL)
-0.001 0.016 0.999 0.998 1.000 -0.002 0.000 0.998 0.997 0.999
Triglyceride (mg/dL) 0.000 0.194 1.000 1.000 1.001 0.000 0.978 1.000 1.000 1.000
Hypertension
No (Reference) 0.000 1.000 1.000
Yes 0.349 0.000 1.417 1.318 1.525 0.001 0.987 1.001 0.915 1.094
Dyslipidemia
No (Reference) 0.000 1.000 1.000
Yes 0.731 0.000 2.077 1.938 2.225 0.224 0.000 1.251 1.149 1.362
T2D Complications
None (reference) 0.000 1.000 1.000
Micro or
Macrovascular
-0.035 0.301 0.966 0.903 1.032 -0.160 0.000 0.852 0.785 0.925
Treatment of T2D
Not using insulin
(reference)
0.000 1.000 1.000
Using Insulin 0.338 0.000 1.402 1.307 1.505 0.573 0.000 1.774 1.628 1.933
a Exp (original regression coefficient).
95% CI: 95% Confidence Interval. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0189755.t004
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p<0.0001) [39]. Further, NICE guideline recommends bariatric surgery as a clinically- and
cost-effective option for obese patients with T2D, particularly those with severe obesity [40].
Altogether, all these data suggests that implementation of a large scale weight loss program
could effectively decrease this multisectorial disease burden.
If we consider that overweight and obesity: a) increased the monthly per capita cost of
hyperglycemia drug treatment by 14 and 38%, respectively; b) result in an annual expenditure
of $172.80 and $448.80, respectively, higher than for T2D patients with normal weight in order
to reach comparable degrees of glycometabolic control and c) overweight/obese people repre-
sent 84% of the Latin American T2D population, these three conditions clearly impose a heavy
burden on the health care budget. Therefore, this situation should alert health policy makers
on the importance of implement effective strategies to reduce overweight and obesity in people
with T2D.
Although clear and significant, our results should be considered with caution due to several
limitations such as a) it is an observational rather than a prospective study; b) the population
studied was not entirely representative of a population base; c) its total number of cases is
strongly influenced by one participating country (Argentina) and d) we have not considered
neither the physical activity load nor adherence to healthy meal plan thus, we do not know
whether such conditions could affect all the BMI conditions in a comparable manner; e) data
were reported by specialized diabetes facilities. However, we have shown that the cost profile
was comparable in every participating country, and other authors have also shown that in dif-
ferent countries the impact of BMI on drug-treatment costs occurs even at the primary care
level [16,17]. In this context, our results seem to reflect a general process rather than local or
other bias.
Conclusions
In brief, our study shows a significant association between BMI and the total cost of drug treat-
ment for T2D and its associated cardiovascular risk factors in Latin America. They also suggest
that implementation of effective obesity preventive strategies might significantly decrease the
burden of T2D on healthcare costs and other social factors.
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